Silodosin

Evidence Level: L5

Predicted Indications: 6

Silodosin

Pharmacist Assessment Report

Silodosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Silodosin is a selective alpha-1A adrenergic receptor antagonist, originally used to treat symptoms of benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but no clinical trials and no publications currently support this prediction, so it is a computational signal only.

Quick Overview

Item	Content
Original Indication	Benign prostatic hyperplasia
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	0.9999
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, silodosin is a selective alpha-1A adrenergic receptor antagonist. Its efficacy in BPH comes from relaxing smooth muscle in the prostate and bladder neck.

The link to the predicted indication is weak. Ambras syndrome is a rare genetic disorder caused by rearrangements in the regulatory region of the TRPS1 gene. There is no established reason why blocking alpha-1A receptors would change it. A possible connection through adrenergic signalling in hair follicles or vascular function is speculative. For comparison, some vasodilating drugs (such as minoxidil) are known to cause hypertrichosis, so a vasoactive drug could plausibly affect hair growth. However, the direction of effect for silodosin is unknown and could be neutral.

The other predictions follow the same pattern, and the data compiled for this report show no clinical or literature support for any of them:

Rank	Predicted Indication	TxGNN Score	Comment
2	Hypertrichosis	0.9999	Computational only; direction of effect unestablished
3	Malformation syndrome with odontal and/or periodontal component	0.9999	No identifiable mechanistic link; the score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence
4	Syndrome with Dandy-Walker malformation as major feature	0.9998	Structural brain anomaly not expected to respond to an alpha-blocker
5	Isolated genetic hair shaft abnormality	0.9998	Hair shaft structure is determined by genetic defects, with no evidence of alpha-1A involvement
6	Familial isolated trichomegaly	0.9923	Speculative and unverified

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Silodosin is marketed in India with 20 valid single-ingredient registrations. Five representative authorizations are listed below. The data compiled for this report contain no approved indication text for any of them.

Authorization Number	Product Name	Dosage Form	Manufacturer
27632	Bphlo S 8mg Tablet	Strip of 10 tablets	Renauxe Pharma India Pvt Ltd
133606	Maxvoid 8 Tablet	Strip of 15 tablets	Alkem Laboratories Ltd
62363	DavaIndia Silodosin 4mg Capsule	Strip of 10 capsules	Davaindia Generic Pharmacy
202928	Silotag 8mg Capsule	Strip of 10 capsules	Jaiwik Biotech
173631	Prostagard-D8 Capsule	Strip of 10 capsules	Aristo Pharmaceuticals Pvt Ltd

All available forms are oral (tablets and capsules). Several products are combinations packaged with a second agent (for example, the 8mg/0.5mg products and the combipacks).

Safety Considerations

Conditions linked to contraindication or caution (from knowledge-graph data, not package insert text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, liver failure, kidney disease, pyoureter, intraoperative floppy iris syndrome.
Drug Interactions: 99 interactions were identified in total. The only Major one among those reviewed is clarithromycin. Moderate interactions include bupropion, aprepitant, morphine, dexamethasone, cimetidine, miconazole, clotrimazole, the SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), dronabinol, nabilone, eliglustat, rolapitant, metreleptin, glycerol phenylbutyrate and opium.

Please refer to the package insert for the official warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a TxGNN model (deep learning) score. There are no clinical trials or publications, and no plausible mechanism links alpha-1A blockade to Ambras syndrome or the other predicted conditions. Silodosin is a safe, widely marketed drug for BPH, but that does not support its use in these rare genetic hair and malformation disorders.

To proceed, the following is needed:

Detailed mechanism of action data, to assess any biological link to hair follicle biology
Preclinical evidence (for example, follicle or cell models) showing an effect of alpha-1A antagonism on hair growth
Package insert warnings and contraindications from the India regulatory source
Assessment of similarity to the original indication and of route compatibility (both currently pending)
If hypertrichosis becomes the focus, a literature review of adrenergic effects on hair growth, noting that the direction of effect is unknown
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.